Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

Clinical Infectious Diseases

Volumn 27, Issue 4, 1998, Pages 764-770

  Doern, Gary V ^a   Pfaller, Michael A ^a   Kugler, Kari ^a   Freeman, Juliana ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFADROXIL; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; UNITED STATES;

EID: 2442727490     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514953     Document Type: Article

References (29)

1. Kislak JW, Razavi LMB, Daly AK, Finland. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965; 250:261-8.
2. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735-40.
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eighth information supplement, M100-S8. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
4. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae. Clin Infect Dis 1992; 15:77-83.
5. Spika JS, Acklam RR, Plikaytis BD, Oxtoby MJ, the Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991; 163: 1273-8.
6. Jorgensen JH, Doem GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34:2075-80.
7. Thornsberry C, Brown SD, Yee C, Bouchillon SK, Marier JK, Rich T. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Suppl Infect Med 1993; 93:15-24.
8. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994; 38:2419-25.
9. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
10. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three third-generation cephalosporins against U.S. isolates of Streptococcus pneumoniae: a 1995 surveillance study. Diagn Microbiol Infect Dis 1996; 25:89-95.
11. Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ, the SPAR Study Group. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis 1998 (in press).
12. Jette LP, Lamothe F, the Pneumococcus Study Group. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 1989; 27:1-5.
13. Mazzulli T, Simor AE, Jaeger R, Fuller S, Low DE. Comparative in vitro activities of several new fluoroquinolones and β-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1990; 34:467-9.
14. Simor AE, Louie M, Low DE, The Canadian Bacterial Surveillance Network. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40:2190-3.
15. Laible G, Hakenbeck R. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae. J Bacteriol 1991; 173:6986-90.
16. Markiewicz Z, Tomasz A. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 1989; 27:405-10.
17. Jamin M, Hakenbeck R, Frere J-M. Penicillin binding protein 2x as a major contributor to intrinsic β-lactam resistance of Streptococcus pneumoniae. FEBS 1993; 331:101-4.
18. Grebe T, Hakenback R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob Agents Chemother 1996; 40:829-34.
19. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992; 30:279-88.
20. Spangler SK, Jacobs JR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 1994; 38:2902-4.
21. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone. Antimicrob Agents Chemother 1994; 38:2905-7.
22. Gross ME, Giron KP, Septimus JD, Mason EO Jr, Musher DM. Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1995; 39:1166-8.
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
24. Sloas MM, Barrett FF, Chesney PJ, et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992; 11:662-6.
25. Friedland IR, Shelton S, Paris M, et al. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993; 12:196-200.
26. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37:1630-6.
27. Paris MM, Ramilo O, McCracken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39:2171-5.
28. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995; 39:271-2.
29. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.